TWO SIGMA ADVISERS, LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 210 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.39 and the average weighting 0.3%.

Quarter-by-quarter ownership
TWO SIGMA ADVISERS, LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$5,219,329
-69.1%
144,700
-67.3%
0.01%
-70.5%
Q1 2023$16,918,170
-50.1%
443,000
-25.7%
0.04%
-53.7%
Q4 2022$33,918,090
+158.7%
596,100
+79.8%
0.10%
+150.0%
Q3 2022$13,111,000
-23.6%
331,600
-15.0%
0.04%
-22.4%
Q2 2022$17,169,000
+7332.5%
390,200
+6627.6%
0.05%
+4800.0%
Q1 2022$231,000
-98.2%
5,800
-98.2%
0.00%
-97.1%
Q3 2021$12,941,000
-46.8%
318,120
-40.6%
0.03%
-46.9%
Q2 2021$24,332,000
+32.5%
535,820
+21.7%
0.06%
+28.0%
Q1 2021$18,361,000
+3.7%
440,420
+6.2%
0.05%
+6.4%
Q4 2020$17,708,000
-38.6%
414,620
-62.2%
0.05%
-42.7%
Q3 2020$28,845,000
-26.6%
1,097,620
-25.1%
0.08%
-28.7%
Q2 2020$39,275,000
+43.1%
1,464,920
-4.0%
0.12%
+9.5%
Q1 2020$27,453,000
+57.0%
1,526,020
+54.7%
0.10%
+156.1%
Q4 2019$17,487,000
+222.3%
986,320
+182.0%
0.04%
+215.4%
Q3 2019$5,426,000
-5.1%
349,820
+5.1%
0.01%
-7.1%
Q2 2019$5,716,000
+22.1%
332,720
+14.4%
0.01%
+16.7%
Q1 2019$4,681,000
-29.7%
290,720
-36.1%
0.01%
-33.3%
Q4 2018$6,657,000
-50.2%
455,020
-38.2%
0.02%
-45.5%
Q3 2018$13,375,000
-15.9%
736,120
-21.9%
0.03%
-23.3%
Q2 2018$15,900,000
-25.8%
942,520
-13.8%
0.04%
-25.9%
Q1 2018$21,422,000
+50.9%
1,093,520
+56.1%
0.06%
+52.6%
Q4 2017$14,197,000
+540.4%
700,720
+449.1%
0.04%
+533.3%
Q3 2017$2,217,000
+480.4%
127,620
+328.0%
0.01%
+500.0%
Q2 2017$382,000
+134.4%
29,820
+136.7%
0.00%0.0%
Q1 2017$163,000
-40.9%
12,600
-20.9%
0.00%
-50.0%
Q4 2015$276,000
-57.4%
15,920
-66.4%
0.00%
-50.0%
Q3 2015$648,000
+103.1%
47,424
+235.9%
0.00%
+100.0%
Q2 2015$319,00014,1200.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2018
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders